Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07151261 · ClinicalTrials.gov registry record · NA
Ashwagandha for Nighttime Waking
A NA study of Disturbed Sleep, sponsored by National University of Natural Medicine.
- Active
- Registry status
- NA
- Development phase
- 54
- Enrollment target
- 1
- Study location
NCT07151261: Active NA study of Disturbed Sleep, sponsored by National University of Natural Medicine.
NCT07151261 is a NA study of Disturbed Sleep that is active but no longer recruiting, run by National University of Natural Medicine. The registered enrollment target is 54 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07151261, a NA study of Disturbed Sleep, is active but no longer recruiting, sponsored by National University of Natural Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 54 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to evaluate the effect of a sustained-release, lower-dosage (150mg) Ashwagandha supplement to reduce disturbed sleep. 54 participants, after randomization, will take either an Ashwagandha supplement or a placebo daily for 28 days (week 4) and wear an Oura ring. The Oura ring will measure waking after sleep onset (WASO). Questionnaires to evaluate quality of life and sleep will be administered at baseline and week 4.
Primary Outcome
WASO is measured nightly in hours and minutes via an Oura Ring. The Oura Ring must be worn at least 4 nights per week on average from Baseline (7 days) + 28 days. Primary analysis: Change in WASO will be measured as the average of the final 4 days of Week 4 minus the average WASO of the Baseline Week. Secondary analysis: Change in WASO will be measured as the average of Week 4 minus the average WASO of the Baseline Week.
Conditions Studied
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Ashwagandha
Study Locations (1)
Oregon
- National University of Natural Medicine - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2025-10-20 |
| Est. Completion | 2026-05-11 |
| Phase | NA |
What the registry record for NCT07151261 still lists
NCT07151261 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Disturbed Sleep appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07151261 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT07151261 about?
NCT07151261 is a clinical study titled "Ashwagandha for Nighttime Waking". The purpose of this research is to evaluate the effect of a sustained-release, lower-dosage (150mg) Ashwagandha supplement to reduce disturbed sleep. 54 participants, after randomization, will take either an Ashwagandha supplement or a placebo daily for 28 days (week 4) and wear an Oura ring. The Ou...
What is the current status of trial NCT07151261?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 54 participants. The study started on 2025-10-20. Estimated completion is 2026-05-11.
What conditions does trial NCT07151261 study?
This clinical trial studies the following conditions: Disturbed Sleep.
What interventions are being tested in trial NCT07151261?
The interventions under investigation include: Placebo (OTHER), Ashwagandha (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07151261?
This trial is sponsored by National University of Natural Medicine, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07151261 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07151261's enrollment target sits among peer trials
54 1268th of 2000 higher than 730 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI